Open Actively Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

About

Brief Summary
Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 2

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Join this Trial

Share:
Study Stats
Protocol No.
24-5358
Category
Breast Cancer
Contact
Aramis Diaz
Location
  • UCLA Beverly Hills
  • UCLA Encino
  • UCLA Parkside
  • UCLA San Luis Obispo
  • UCLA Santa Clarita
  • UCLA Santa Monica
  • UCLA Torrance
  • UCLA Ventura
  • UCLA Westlake Village
For Providers
NCT No.
NCT06369285
For detailed technical eligibility, visit ClinicalTrials.gov.